Schering-Plough to Initiate Phase III Studies With Boceprevir

[Guest guest]

Schering-Plough to Initiate Phase III Studies With Boceprevir

From PR Newswire Europe (inc. UK Disclose) - May 21, 2008

KENILWORTH, N.J., May 21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation ,

a leader in hepatitis research, today announced that it is initiating two large

Phase III studies of boceprevir, its investigational oral hepatitis C protease

inhibitor, in patients chronically infected with hepatitis C virus genotype 1.

One study will be in previously untreated (naive) patients and the other in

patients who failed prior treatment (relapsers and nonresponders), an area of

great unmet medical need.

_________________________________________________________________

E-mail for the greater good. Join the i’m Initiative from Microsoft.

http://im.live.com/Messenger/IM/Join/Default.aspx?source=EML_WL_ GreaterGood